{"transactions":[{"id":834495,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-18T20:05:48.000Z","date":"2026-03-16","kind":"sale","planned":false,"acquired":false,"shares":47763,"price":2.47,"value":117974.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program."}],"balance_after":5150599,"source":{"system":"sec-edgar","filing":"0001737287-26-000013","document":"wk-form4_1773864344.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728726000013/wk-form4_1773864344.xml","form_type":"4"}},{"id":919032,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-02-04T22:18:18.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":392586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."}],"balance_after":392586,"derivative":{"underlying":"Common Stock","underlying_shares":392586},"source":{"system":"sec-edgar","filing":"0001737287-26-000009","document":"wk-form4_1770243495.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728726000009/wk-form4_1770243495.xml","form_type":"4"}},{"id":919031,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-04T22:18:18.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":1387931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":1387931,"derivative":{"exercise_price":1.87,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":1387931},"source":{"system":"sec-edgar","filing":"0001737287-26-000009","document":"wk-form4_1770243495.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728726000009/wk-form4_1770243495.xml","form_type":"4"}},{"id":919030,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-04T22:18:18.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":95269,"price":1.8,"value":171484.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.87, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,562 shares of the Issuer's common stock acquired by the reporting person on September 15, 2025 pursuant to an employee stock purchase program."}],"balance_after":5185862,"source":{"system":"sec-edgar","filing":"0001737287-26-000009","document":"wk-form4_1770243495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728726000009/wk-form4_1770243495.xml","form_type":"4"}},{"id":1198656,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-18T21:30:50.000Z","date":"2025-03-14","kind":"sale","planned":false,"acquired":false,"shares":46668,"price":1.96,"value":91469.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in one transaction at a single price point of $1.96. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at the price set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 6000 shares of the Issuer's common stock acquired by the reporting person on March 14, 2025 pursuant to an employee stock purchase program."}],"balance_after":5276569,"source":{"system":"sec-edgar","filing":"0001737287-25-000042","document":"wk-form4_1742333443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728725000042/wk-form4_1742333443.xml","form_type":"4"}},{"id":1281432,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-05T21:13:43.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":46003,"price":1.68,"value":77285.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.68 to $1.69, inclusive. The reporting person undertakes to\nprovide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above."}],"balance_after":5317237,"source":{"system":"sec-edgar","filing":"0001737287-25-000017","document":"wk-form4_1738790016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728725000017/wk-form4_1738790016.xml","form_type":"4"}},{"id":1292812,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2025-01-29T01:10:50.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":1952130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":1952130,"derivative":{"exercise_price":1.94,"expiration_date":"2035-01-24","underlying":"Common Stock","underlying_shares":1952130},"source":{"system":"sec-edgar","filing":"0001737287-25-000004","document":"wk-form4_1738113042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728725000004/wk-form4_1738113042.xml","form_type":"4"}},{"id":1292811,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-29T01:10:50.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":552174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 960 shares of the Issuer's common stock acquired by the reporting person on September 15, 2024 pursuant to an employee stock purchase program."}],"balance_after":5363240,"source":{"system":"sec-edgar","filing":"0001737287-25-000004","document":"wk-form4_1738113042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728725000004/wk-form4_1738113042.xml","form_type":"4"}},{"id":1508547,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-05-20T22:01:27.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":344828,"price":2.9,"value":1000001.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the \"Issuer\") in a registered direct offering."}],"balance_after":4810106,"source":{"system":"sec-edgar","filing":"0001593968-24-000714","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000159396824000714/primary_01.xml","form_type":"4"}},{"id":1571920,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-19T00:10:36.000Z","date":"2024-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":53393,"price":4.33,"value":231191.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.29 to $4.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,468 shares of the Issuer's common stock acquired by the reporting person on March 15, 2024 pursuant to an employee stock purchase program."}],"balance_after":4465278,"source":{"system":"sec-edgar","filing":"0001593968-24-000477","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000159396824000477/primary_01.xml","form_type":"4"}},{"id":1664807,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-31T22:42:37.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":1123535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter."}],"balance_after":1123535,"derivative":{"exercise_price":3.2,"expiration_date":"2034-01-25","underlying":"Common Stock","underlying_shares":1123535},"source":{"system":"sec-edgar","filing":"0001593968-24-000192","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000159396824000192/primary_01.xml","form_type":"4"}},{"id":1664806,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-31T22:42:37.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":317800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1492 shares of the Issuer's common stock acquired by the reporting person on September 15,2023 pursuant to an employee stock purchase program."}],"balance_after":4513203,"source":{"system":"sec-edgar","filing":"0001593968-24-000192","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000159396824000192/primary_01.xml","form_type":"4"}},{"id":1938943,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-25T00:13:19.000Z","date":"2023-03-22","kind":"grant","planned":false,"acquired":true,"shares":1492200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":1492200,"derivative":{"exercise_price":5.04,"expiration_date":"2033-03-22","underlying":"Common Stock","underlying_shares":1492200},"source":{"system":"sec-edgar","filing":"0001593968-23-000521","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000159396823000521/primary_01.xml","form_type":"4"}},{"id":1938942,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-25T00:13:19.000Z","date":"2023-03-22","kind":"grant","planned":false,"acquired":true,"shares":1924464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 1,480,357 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period."}],"balance_after":4193911,"source":{"system":"sec-edgar","filing":"0001593968-23-000521","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000159396823000521/primary_01.xml","form_type":"4"}},{"id":1949619,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-16T21:32:26.000Z","date":"2023-03-14","kind":"tax_withholding","acquired":false,"shares":22340,"price":5.56,"value":124210.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.49 to $5.595, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 135 and 2000 share of the Issuer's common stock acquired by the reporting person on September 15, 2021 and on March 15, 2023 pursuant to an employee stock purchase program, respectively."}],"balance_after":2269447,"source":{"system":"sec-edgar","filing":"0001737287-23-000025","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728723000025/primary_doc.xml","form_type":"4"}},{"id":2317455,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-25T21:51:39.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":2195512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter"}],"balance_after":2195512,"derivative":{"exercise_price":9.69,"expiration_date":"2032-03-23","underlying":"Common Stock","underlying_shares":2195512},"source":{"system":"sec-edgar","filing":"0001214659-22-004374","document":"marketforms-55851.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465922004374/marketforms-55851.xml","form_type":"4"}},{"id":2326279,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-17T21:59:06.000Z","date":"2022-03-15","kind":"sale","acquired":false,"shares":23648,"price":7.6488,"value":180878.8224,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.59 to $7.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1021 shares of the Issuer's common stock acquired by the reporting person on March 15, 2022 pursuant to an employee stock purchase program."}],"balance_after":2289652,"source":{"system":"sec-edgar","filing":"0001214659-22-004085","document":"marketforms-55821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465922004085/marketforms-55821.xml","form_type":"4"}},{"id":2694641,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-26T12:00:20.000Z","date":"2021-05-24","kind":"exercise","acquired":false,"shares":27410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":541190,"derivative":{"exercise_price":18.22,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":27410},"source":{"system":"sec-edgar","filing":"0001214659-21-005927","document":"marketforms-52929.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465921005927/marketforms-52929.xml","form_type":"4"}},{"id":2694640,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-05-26T12:00:20.000Z","date":"2021-05-24","kind":"exercise","acquired":true,"shares":27410,"price":18.22,"value":499410.2,"ownership":{"direct":true},"balance_after":2312279,"source":{"system":"sec-edgar","filing":"0001214659-21-005927","document":"marketforms-52929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465921005927/marketforms-52929.xml","form_type":"4"}},{"id":2760395,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-02T20:11:34.000Z","date":"2020-08-31","kind":"gift","acquired":true,"shares":205778,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On August 31, 2020, Robert Chang transferred 205,778 shares of the Issuer's common stock to the RTC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's son is the beneficiary."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities held in the name of the RTC 2019 Trust dated October 1, 2019."}],"balance_after":856044,"source":{"system":"sec-edgar","filing":"0001214659-21-003892","document":"marketforms-52165.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465921003892/marketforms-52165.xml","form_type":"4/A","original_submission_date":"2021-03-30"}},{"id":2760394,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-02T20:11:34.000Z","date":"2020-08-31","kind":"gift","acquired":true,"shares":205778,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 31, 2020, Julia Chang transferred 205,778 shares of the Issuer's common stock to the JEC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's daughter is the beneficiary."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities held in the name of the JEC 2019 Trust dated October 1, 2019."}],"balance_after":856044,"source":{"system":"sec-edgar","filing":"0001214659-21-003892","document":"marketforms-52165.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465921003892/marketforms-52165.xml","form_type":"4/A","original_submission_date":"2021-03-30"}},{"id":2767550,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-30T20:57:27.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":298836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the stock option shall vest on March 13, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":298836,"derivative":{"exercise_price":33.78,"expiration_date":"2031-03-26","underlying":"Common Stock","underlying_shares":298836},"source":{"system":"sec-edgar","filing":"0001214659-21-003609","document":"marketforms-52127.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465921003609/marketforms-52127.xml","form_type":"4"}},{"id":2767549,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-30T20:57:27.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":80452,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2284869,"source":{"system":"sec-edgar","filing":"0001214659-21-003609","document":"marketforms-52127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465921003609/marketforms-52127.xml","form_type":"4"}},{"id":2780970,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-17T21:00:53.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":20513,"price":38.5741,"value":791270.5133,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.97 to $38.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 276 shares of the Issuer's common stock acquired by the reporting person on September 15, 2020 and includes 553 shares of the Issuer's common stock acquired by the reporting person on March 15, 2021 pursuant to an employee stock purchase program."}],"balance_after":2204417,"source":{"system":"sec-edgar","filing":"0001214659-21-003240","document":"marketforms-51920.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465921003240/marketforms-51920.xml","form_type":"4"}},{"id":3168113,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-28T20:32:54.000Z","date":"2020-03-18","kind":"gift","acquired":true,"shares":428022,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On March 18, 2020, the Robert Chang 2018 Irrevocable Trust transferred 428,022 shares of the Issuer's common stock to the RTC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's son is the beneficiary."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Securities held in the name of the RTC 2019 Trust dated October 1, 2019."}],"balance_after":650266,"source":{"system":"sec-edgar","filing":"0001214659-20-003819","document":"marketforms-48643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465920003819/marketforms-48643.xml","form_type":"4"}},{"id":3168112,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-28T20:32:54.000Z","date":"2020-03-18","kind":"gift","acquired":true,"shares":428022,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 18, 2020, the Julia Chang 2018 Irrevocable Trust transferred 428,022 shares of the Issuer's common stock to the JEC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's daughter is the beneficiary."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities held in the name of the JEC 2019 Trust dated October 1, 2019."}],"balance_after":650266,"source":{"system":"sec-edgar","filing":"0001214659-20-003819","document":"marketforms-48643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465920003819/marketforms-48643.xml","form_type":"4"}},{"id":3168111,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-28T20:32:54.000Z","date":"2020-04-24","kind":"other","acquired":true,"shares":9187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":2224101,"source":{"system":"sec-edgar","filing":"0001214659-20-003819","document":"marketforms-48643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465920003819/marketforms-48643.xml","form_type":"4"}},{"id":3168110,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-28T20:32:54.000Z","date":"2020-04-24","kind":"other","acquired":true,"shares":9198,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":1201108,"source":{"system":"sec-edgar","filing":"0001214659-20-003819","document":"marketforms-48643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465920003819/marketforms-48643.xml","form_type":"4"}},{"id":3198928,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T20:37:55.000Z","date":"2020-03-18","kind":"grant","acquired":true,"shares":568600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":568600,"derivative":{"exercise_price":18.22,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":568600},"source":{"system":"sec-edgar","filing":"0001214659-20-002806","document":"marketforms-48390.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465920002806/marketforms-48390.xml","form_type":"4"}},{"id":3201791,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-18T20:31:26.000Z","date":"2020-03-16","kind":"sale","acquired":false,"shares":1625,"price":20.0634,"value":32603.025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.  This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.89 to $20.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 1,113 shares of the Issuer's common stock acquired by the reporting person on March 16, 2020 pursuant to an employee stock purchase program."}],"balance_after":2214914,"source":{"system":"sec-edgar","filing":"0001214659-20-002734","document":"marketforms-48339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465920002734/marketforms-48339.xml","form_type":"4"}},{"id":3201790,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-18T20:31:26.000Z","date":"2020-03-16","kind":"sale","acquired":false,"shares":18710,"price":19.2417,"value":360012.207,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.  This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.88 to $19.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":2215426,"source":{"system":"sec-edgar","filing":"0001214659-20-002734","document":"marketforms-48339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465920002734/marketforms-48339.xml","form_type":"4"}},{"id":3214971,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-11T20:38:19.000Z","date":"2020-03-04","kind":"other","acquired":true,"shares":9391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":2234136,"source":{"system":"sec-edgar","filing":"0001214659-20-002528","document":"marketforms-48290.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465920002528/marketforms-48290.xml","form_type":"4"}},{"id":3214970,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-11T20:38:19.000Z","date":"2020-03-04","kind":"other","acquired":true,"shares":9402,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":1191910,"source":{"system":"sec-edgar","filing":"0001214659-20-002528","document":"marketforms-48290.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465920002528/marketforms-48290.xml","form_type":"4"}},{"id":3362656,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-11-21T21:38:58.000Z","date":"2019-11-19","kind":"other","acquired":true,"shares":9391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":2224745,"source":{"system":"sec-edgar","filing":"0001214659-19-007333","document":"marketforms-46372.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465919007333/marketforms-46372.xml","form_type":"4"}},{"id":3362655,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-11-21T21:38:58.000Z","date":"2019-11-19","kind":"other","acquired":true,"shares":9402,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":1182508,"source":{"system":"sec-edgar","filing":"0001214659-19-007333","document":"marketforms-46372.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465919007333/marketforms-46372.xml","form_type":"4"}},{"id":3386090,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-30T00:08:21.000Z","date":"2019-10-25","kind":"other","acquired":true,"shares":9391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":2215354,"source":{"system":"sec-edgar","filing":"0001214659-19-006703","document":"marketforms-45997.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465919006703/marketforms-45997.xml","form_type":"4"}},{"id":3386089,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-30T00:08:21.000Z","date":"2019-10-25","kind":"other","acquired":true,"shares":9402,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":1173106,"source":{"system":"sec-edgar","filing":"0001214659-19-006703","document":"marketforms-45997.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465919006703/marketforms-45997.xml","form_type":"4"}},{"id":3406205,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-25T22:27:25.000Z","date":"2019-09-23","kind":"other","acquired":true,"shares":9391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 1,103 shares of the Issuer's common stock acquired by the reporting person on September 13, 2019 pursuant to an employee stock purchase program."}],"balance_after":2205963,"source":{"system":"sec-edgar","filing":"0001214659-19-006021","document":"marketforms-45834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465919006021/marketforms-45834.xml","form_type":"4"}},{"id":3406204,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-25T22:27:25.000Z","date":"2019-09-23","kind":"other","acquired":true,"shares":9402,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":1163704,"source":{"system":"sec-edgar","filing":"0001214659-19-006021","document":"marketforms-45834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465919006021/marketforms-45834.xml","form_type":"4"}},{"id":3419288,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-09T22:03:33.000Z","date":"2019-09-05","kind":"other","acquired":true,"shares":9391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":2195469,"source":{"system":"sec-edgar","filing":"0001214659-19-005741","document":"marketforms-45712.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465919005741/marketforms-45712.xml","form_type":"4"}},{"id":3419287,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-09T22:03:33.000Z","date":"2019-09-05","kind":"other","acquired":true,"shares":9402,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust.  The reporting person resigned as Trustee of the Julia Chang 2018 Irrevocable Trust and the Robert Chang 2018 Irrevocable Trust and no longer has a reportable beneficial interest in the 1,696,044 shares included in the reporting person's prior ownership reports."}],"balance_after":1154302,"source":{"system":"sec-edgar","filing":"0001214659-19-005741","document":"marketforms-45712.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000121465919005741/marketforms-45712.xml","form_type":"4"}},{"id":3457812,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-07-22T20:26:06.000Z","date":"2019-07-18","kind":"other","acquired":true,"shares":9391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":2186078,"source":{"system":"sec-edgar","filing":"0001209191-19-042874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919119042874/doc4.xml","form_type":"4"}},{"id":3457811,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-07-22T20:26:06.000Z","date":"2019-07-18","kind":"other","acquired":true,"shares":9402,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":1144900,"source":{"system":"sec-edgar","filing":"0001209191-19-042874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919119042874/doc4.xml","form_type":"4"}},{"id":3462353,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-07-12T21:10:34.000Z","date":"2019-07-10","kind":"other","acquired":true,"shares":6388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":2176687,"source":{"system":"sec-edgar","filing":"0001209191-19-041955","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919119041955/doc4.xml","form_type":"4"}},{"id":3462352,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-07-12T21:10:34.000Z","date":"2019-06-18","kind":"other","acquired":true,"shares":10154,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":1135498,"source":{"system":"sec-edgar","filing":"0001209191-19-041955","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919119041955/doc4.xml","form_type":"4"}},{"id":3525562,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-05-15T21:09:38.000Z","date":"2019-05-13","kind":"other","acquired":true,"shares":11753,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":1125344,"source":{"system":"sec-edgar","filing":"0001209191-19-030076","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919119030076/doc4.xml","form_type":"4"}},{"id":3545255,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-04-30T23:22:51.000Z","date":"2019-04-26","kind":"other","acquired":true,"shares":11753,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":1113591,"source":{"system":"sec-edgar","filing":"0001209191-19-026676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919119026676/doc4.xml","form_type":"4"}},{"id":3592301,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-03-15T21:19:40.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":292700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":292700,"derivative":{"exercise_price":26.89,"expiration_date":"2029-03-12","underlying":"Common Stock","underlying_shares":292700},"source":{"system":"sec-edgar","filing":"0001209191-19-019755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919119019755/doc4.xml","form_type":"4"}},{"id":3592300,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-03-15T21:19:40.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":173000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2168625,"source":{"system":"sec-edgar","filing":"0001209191-19-019755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919119019755/doc4.xml","form_type":"4"}},{"id":3787918,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-10-17T21:30:08.000Z","date":"2018-10-15","kind":"exercise","acquired":false,"shares":5704,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":29946},"source":{"system":"sec-edgar","filing":"0001209191-18-055374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919118055374/doc4.xml","form_type":"4"}},{"id":3787917,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-10-17T21:30:08.000Z","date":"2018-10-15","kind":"exercise","acquired":true,"shares":29946,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities held in the name of the Chang 2006 Family Trust."}],"balance_after":1101838,"source":{"system":"sec-edgar","filing":"0001209191-18-055374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919118055374/doc4.xml","form_type":"4"}},{"id":3787916,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-10-17T21:30:08.000Z","date":"2018-10-15","kind":"purchase","acquired":true,"shares":40000,"price":18,"value":720000.0,"ownership":{"direct":true},"balance_after":1995625,"source":{"system":"sec-edgar","filing":"0001209191-18-055374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000120919118055374/doc4.xml","form_type":"4"}},{"id":4190756,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-05T20:12:59.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":90600,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":46.09,"expiration_date":"2026-12-21","underlying":"Common Stock","underlying_shares":90600},"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190755,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-05T20:12:59.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":37181,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":63.87,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":37181},"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190754,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-05T20:12:59.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":28919,"price":116.13,"value":3358363.47,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":63.87,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":28919},"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190753,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-05T20:12:59.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":23437,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":51.96,"expiration_date":"2024-12-23","underlying":"Common Stock","underlying_shares":23437},"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190752,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-05T20:12:59.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":51563,"price":128.04,"value":6602126.52,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":51.96,"expiration_date":"2024-12-23","underlying":"Common Stock","underlying_shares":51563},"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190751,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-05T20:12:59.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":56250,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a \"Company Option\") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into\nan option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option provided for 25% vesting on June 2, 2015, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":6.89,"expiration_date":"2024-06-05","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190750,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-10-05T20:12:59.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":116750,"price":173.11,"value":20210592.5,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option provided for 25% vesting on June 2, 2015, and vesting thereafter in 36 equal monthly installments."}],"balance_after":0,"derivative":{"exercise_price":6.89,"expiration_date":"2024-06-05","underlying":"Common Stock","underlying_shares":116750},"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190749,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-10-05T20:12:59.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":38675,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a \"Company Restricted Stock Unit\"), held by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the \"Equity Award Conversion Ratio\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the \"Equity Award Conversion Ratio\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190748,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-10-05T20:12:59.000Z","date":"2017-10-03","kind":"other","acquired":false,"shares":16605,"price":180,"value":2988900.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes."}],"balance_after":38675,"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190747,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-10-05T20:12:59.000Z","date":"2017-09-20","kind":"gift","acquired":false,"shares":570,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":55280,"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190746,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-10-05T20:12:59.000Z","date":"2017-09-13","kind":"gift","acquired":false,"shares":157,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":55850,"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190745,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-10-05T20:12:59.000Z","date":"2017-09-12","kind":"gift","acquired":false,"shares":1041,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":56007,"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4190744,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-10-05T20:12:59.000Z","date":"2017-09-11","kind":"gift","acquired":false,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":57048,"source":{"system":"sec-edgar","filing":"0001209191-17-056218","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117056218/doc4.xml","form_type":"4"}},{"id":4200675,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-09-27T21:40:34.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":7927,"price":179.6639,"value":1424195.7353,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU."}],"balance_after":57423,"source":{"system":"sec-edgar","filing":"0001209191-17-054196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117054196/doc4.xml","form_type":"4"}},{"id":4200674,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-09-27T21:40:34.000Z","date":"2017-09-25","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 185 shares acquired under the 2014 Employee Stock Purchase Plan on August 18, 2017."}],"balance_after":65350,"source":{"system":"sec-edgar","filing":"0001209191-17-054196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117054196/doc4.xml","form_type":"4"}},{"id":4334650,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-05-03T18:06:57.000Z","date":"2017-05-01","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the 300,000 shares subject to the stock option vested and became exercisable on June 2, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":123000,"derivative":{"exercise_price":6.89,"expiration_date":"2024-06-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-029753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117029753/doc4.xml","form_type":"4"}},{"id":4334649,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-05-03T18:06:57.000Z","date":"2017-05-01","kind":"sale","acquired":false,"shares":300,"price":83.36,"value":25008.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.27 to $83.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":50165,"source":{"system":"sec-edgar","filing":"0001209191-17-029753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117029753/doc4.xml","form_type":"4"}},{"id":4334648,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-05-03T18:06:57.000Z","date":"2017-05-01","kind":"sale","acquired":false,"shares":5905,"price":82.6,"value":487753.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.25 to $83.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":50465,"source":{"system":"sec-edgar","filing":"0001209191-17-029753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117029753/doc4.xml","form_type":"4"}},{"id":4334647,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-05-03T18:06:57.000Z","date":"2017-05-01","kind":"sale","acquired":false,"shares":13795,"price":81.84,"value":1128982.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.26 to $82.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":56370,"source":{"system":"sec-edgar","filing":"0001209191-17-029753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117029753/doc4.xml","form_type":"4"}},{"id":4334646,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-05-03T18:06:57.000Z","date":"2017-05-01","kind":"exercise","acquired":true,"shares":20000,"price":6.89,"value":137800.0,"ownership":{"direct":true},"balance_after":70165,"source":{"system":"sec-edgar","filing":"0001209191-17-029753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117029753/doc4.xml","form_type":"4"}},{"id":4360015,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-04-04T16:17:43.000Z","date":"2017-04-03","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the 300,000 shares subject to the stock option vested and became exercisable on June 2, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":143000,"derivative":{"exercise_price":6.89,"expiration_date":"2024-06-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-024746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117024746/doc4.xml","form_type":"4"}},{"id":4360014,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-04-04T16:17:43.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":700,"price":83.66,"value":58562.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.42 to $83.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":50165,"source":{"system":"sec-edgar","filing":"0001209191-17-024746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117024746/doc4.xml","form_type":"4"}},{"id":4360013,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-04-04T16:17:43.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":8697,"price":82.6,"value":718372.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.29 to $83.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":50865,"source":{"system":"sec-edgar","filing":"0001209191-17-024746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117024746/doc4.xml","form_type":"4"}},{"id":4360012,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-04-04T16:17:43.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":3549,"price":82,"value":291018.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.30 to $82.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":59562,"source":{"system":"sec-edgar","filing":"0001209191-17-024746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117024746/doc4.xml","form_type":"4"}},{"id":4360011,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-04-04T16:17:43.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":2424,"price":80.44,"value":194986.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.07 to $80.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":63111,"source":{"system":"sec-edgar","filing":"0001209191-17-024746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117024746/doc4.xml","form_type":"4"}},{"id":4360010,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-04-04T16:17:43.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":3939,"price":79.63,"value":313662.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.07 to $80.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":65535,"source":{"system":"sec-edgar","filing":"0001209191-17-024746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117024746/doc4.xml","form_type":"4"}},{"id":4360009,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-04-04T16:17:43.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":691,"price":78.53,"value":54264.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.05 to $78.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":69474,"source":{"system":"sec-edgar","filing":"0001209191-17-024746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117024746/doc4.xml","form_type":"4"}},{"id":4360008,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-04-04T16:17:43.000Z","date":"2017-04-03","kind":"exercise","acquired":true,"shares":20000,"price":6.89,"value":137800.0,"ownership":{"direct":true},"balance_after":70165,"source":{"system":"sec-edgar","filing":"0001209191-17-024746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919117024746/doc4.xml","form_type":"4"}},{"id":4408519,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option(Right to Buy)","published_at":"2017-03-02T06:08:33.000Z","date":"2017-03-01","kind":"exercise","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the 300,000 shares subject to the stock option vested and became exercisable on June 2, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":163000,"derivative":{"exercise_price":6.89,"expiration_date":"2024-06-05","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-17-005893","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000089924317005893/doc4.xml","form_type":"4"}},{"id":4408518,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-03-02T06:08:33.000Z","date":"2017-03-01","kind":"sale","acquired":false,"shares":4735,"price":79.71,"value":377426.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.60 to $79.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":50165,"source":{"system":"sec-edgar","filing":"0000899243-17-005893","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000089924317005893/doc4.xml","form_type":"4"}},{"id":4408517,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-03-02T06:08:33.000Z","date":"2017-03-01","kind":"sale","acquired":false,"shares":55265,"price":79.11,"value":4372014.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.60 to $79.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":54900,"source":{"system":"sec-edgar","filing":"0000899243-17-005893","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000089924317005893/doc4.xml","form_type":"4"}},{"id":4408516,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2017-03-02T06:08:33.000Z","date":"2017-03-01","kind":"exercise","acquired":true,"shares":60000,"price":6.89,"value":413400.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 242 shares acquired under the 2014 Employee Stock Purchase Plan on February 17, 2017."}],"balance_after":110165,"source":{"system":"sec-edgar","filing":"0000899243-17-005893","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000089924317005893/doc4.xml","form_type":"4"}},{"id":4511746,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-12-27T17:28:09.000Z","date":"2016-12-22","kind":"grant","acquired":true,"shares":90600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest and become exercisable on the first anniversary of the grant date, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":90600,"derivative":{"exercise_price":46.09,"expiration_date":"2026-12-22","underlying":"Common Stock","underlying_shares":90600},"source":{"system":"sec-edgar","filing":"0001209191-16-156833","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919116156833/doc4.xml","form_type":"4"}},{"id":4511745,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2016-12-27T17:28:09.000Z","date":"2016-12-22","kind":"grant","acquired":true,"shares":24800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":49923,"source":{"system":"sec-edgar","filing":"0001209191-16-156833","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919116156833/doc4.xml","form_type":"4"}},{"id":4513030,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D, Chief Medical Off."}}],"security":"Common Stock","published_at":"2016-12-22T16:50:16.000Z","date":"2016-12-20","kind":"sale","acquired":false,"shares":1788,"price":50.86,"value":90937.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold to cover the tax obligation that occurred upon the vesting of an RSU."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 821 shares acquired under the 2014 Employee Stock Purchase Plan (the \"ESPP\") on February 19, 2016 and 686 shares acquired under the ESPP on August 19, 2016."}],"balance_after":25123,"source":{"system":"sec-edgar","filing":"0001209191-16-156547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510580/000120919116156547/doc4.xml","form_type":"4"}}]}